Lowering low-density lipoprotein cholesterol by PCSK9 inhibition in patients with diabetes on insulin therapy: is it efficacious and safe?

Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of the excess morbidity and mortality for individuals with diabetes (1). Patients with type 2 diabetes have an atherogenic lipid profile characterized by elevated non-high-density lipoprotein cholesterol (non-HDL-C), apolipoprotein B (apoB) and triglycerides (TG), along with low HDLcholesterol.